Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06476210RecruitingPhase 4
New drug combo for drug-resistant tuberculosis
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Hefei, AnhuiAges 18 years+ - NCT06477237RecruitingPhase 3
Testing a new psoriasis shot for moderate to severe plaque
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Jiangmen, GuangdongAges 18–75 - NCT06477536RecruitingPhase 2/Phase 3
Long-term safety study of HB0034 for GPP
This trial is for people who have already taken part in an earlier study of the drug HB0034 for generalized pustular psoriasis (GPP). It checks how safe and effective the drug is over a longer period of time.
BeijingAges 18–75 - NCT06478225Recruiting
Cell therapy for advanced pancreatic cancer
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06479343Recruiting
Liquid embolic for brain vessel malformations
This trial tests a new liquid material (called a liquid embolic system) that is injected into the abnormal blood vessels in the brain to block them off. It is for people who have a cerebrovascular malformation and can be treated with a catheter from inside the blood vessel.
Guangzhou, GuangdongAges 18–80 - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
TianjinAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06481410Recruiting
Methylene blue for severe septic shock
This trial is testing whether a medication called methylene blue can help people with severe septic shock who are already on strong blood pressure support (norepinephrine). The goal is to see if it improves survival and reduces the need for other treatments.
Hangzhou, ZhejiangAges Any age - NCT06481566Recruiting
Almonertinib plus radiation for EGFR-mutant lung cancer
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06482905RecruitingPhase 1
CAR-T cell therapy for recurrent grade 4 brain tumors
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Phoenix, ArizonaAges 18–75 - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75 - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT05419492RecruitingPhase 1/Phase 2
ETX101 for children with SCN1A Dravet syndrome
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
San Francisco, CaliforniaAges 6 months–17 years - NCT07441135Recruiting
Injectable gel for body contouring and volumizing
This study tests a gel made of hyaluronic acid (a natural substance in the body) to improve the shape and volume of larger body areas like the buttocks, thighs, or abdomen. It may help with concerns like loose skin, unevenness, or cellulite.
Madrid, MadridAges 18 years+ - NCT07263230RecruitingPhase 2
Roflumilast Foam for Hidradenitis Suppurativa
This study tests whether roflumilast foam (a prescription foam) is safe and can reduce inflamed bumps in people with mild-to-moderate hidradenitis suppurativa (HS) who do not have draining tunnels. Participants will stop other HS treatments during the trial.
Boston, MassachusettsAges 18 years+ - NCT06488625RecruitingPhase 2/Phase 3
Nicotinamide for mild to moderate ulcerative colitis
This trial tests whether a special oral form of nicotinamide (a type of vitamin B3) can help control mild to moderate ulcerative colitis. The pill is designed to release the medication in the lower part of your gut, where UC often affects. Participation involves taking the study drug and having regular checkups to see how your symptoms and inflammation respond.
Kiel, Schleswig-HolsteinAges 18–80 - NCT06492720Recruiting
Testing focused ultrasound for drug-resistant epilepsy
This study tests a new device called NaviFUS that uses focused sound waves to gently stimulate a small area of the brain. It is for people whose seizures start in one part of the brain and are not fully controlled by seizure medicines.
TaipeiAges 18–65 - NCT06494124Recruiting
Brain stimulation for schizophrenia symptoms
This study compares two types of mild brain stimulation—tACS and tDCS—to see if they can help reduce symptoms of schizophrenia. It is for people who have had moderate to severe symptoms for at least two years and are on stable medications.
Bhubaneswar, OdishaAges 18–60 - NCT06494683Recruiting
Kudzu root as an add-on treatment for type 2 diabetes
This trial tests if adding kudzu root (a traditional Chinese herb) to your current diabetes treatment helps control blood sugar better. It is for people with type 2 diabetes whose blood sugar is not well managed despite medication or lifestyle changes.
Nanchang, JiangxiAges 18–80 - NCT06496412Recruiting
Fecal transplant for brain health in type 1 diabetes
This trial tests whether transplanting healthy bacteria into your gut can improve memory and thinking skills in people with long-term type 1 diabetes. If you have had type 1 diabetes for 10 years or more, this study may help find a new way to protect your brain.
Changsha, HunanAges 18–60 - NCT06496971RecruitingPhase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
TaipeiAges 18–80 - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06497452Recruiting
Glofitamab with rescue therapy for relapsed B-cell lymphoma
This study is testing how well the drug Glofitamab works when given along with standard rescue treatments for adults with B-cell Non-Hodgkin Lymphoma that has relapsed or not responded to prior therapy. The goal is to see if this combination is effective and safe in everyday medical practice.
Suzhou, JiangsuAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.